|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Article |
Address correspondence to Erwin F. Wagner, Research Institute of Molecular Pathology, Dr. Bohr-Gasse 7, A-1030 Vienna, Austria. Tel.: 43-1-797-30-888. Fax: 43-1-798-71-53. email: wagner{at}imp.univie.ac.at
Because JunB is an essential gene for placentation, it was conditionally deleted in the embryo proper. JunB
/
mice are born viable, but develop severe low turnover osteopenia caused by apparent cell-autonomous osteoblast and osteoclast defects before a chronic myeloid leukemia-like disease. Although JunB was reported to be a negative regulator of cell proliferation, junB
/
osteoclast precursors and osteoblasts show reduced proliferation along with a differentiation defect in vivo and in vitro. Mutant osteoblasts express elevated p16INK4a levels, but exhibit decreased cyclin D1 and cyclin A expression. Runx2 is transiently increased during osteoblast differentiation in vitro, whereas mature osteoblast markers such as osteocalcin and bone sialoprotein are strongly reduced. To support a cell-autonomous function of JunB in osteoclasts, junB was inactivated specifically in the macrophageosteoclast lineage. Mutant mice develop an osteopetrosis-like phenotype with increased bone mass and reduced numbers of osteoclasts. Thus, these data reveal a novel function of JunB as a positive regulator controlling primarily osteoblast as well as osteoclast activity.
Key Words: AP-1; conditional gene targeting; osteoblasts; osteopenia; osteopetrosis
Abbreviations used in this paper: AP-1, activator protein-1; CML, chronic myeloid leukemia; ES, embryonic stem; M-CSF, macrophage colonystimulating factor; MMP-9, matrix metalloproteinase-9; RANKL, receptor activator of NF
B ligand; TRAP, tartrate-resistant acid phosphatase.
Related Article
|
|